Redeker A G, Mosley J W, Gocke D J, McKee A P, Pollack W
N Engl J Med. 1975 Nov 20;293(21):1055-9. doi: 10.1056/NEJM197511202932101.
Because the value of usual immune globulin preparations in preventing Type B hepatitis is doubtful, we carried out a double-blind comparison of a control human immune globulin preparation with one--identified as HBIG--that had a high concentration (442 mug per milliliter) of antibodies to surface components of hepatitis B virus. Effectiveness was tested in spouses of patients with acute Type B hepatitis. Within 150 days after injection, nine of 33 spouses in the control group had symptomatic Type B hepatitis, compared with one of 25 spouses receiving HBIG. One non-B case also occurred in the HBIG group. Five control globulin recipients had evidence of subclinical hepatitis B infection, compared with one HBIG recipient. Thus, HBIG appeared effective in suppressing not only disease, but also infection itself. Prophylactic value has been demonstrated in persons who should now be recognized as being at exceptionally high risk.
由于常规免疫球蛋白制剂在预防乙型肝炎方面的价值存疑，我们对一种对照人免疫球蛋白制剂与一种（被鉴定为乙肝免疫球蛋白）含有高浓度（每毫升442微克）乙肝病毒表面成分抗体的制剂进行了双盲比较。在急性乙型肝炎患者的配偶中测试其有效性。注射后150天内，对照组33名配偶中有9人出现有症状的乙型肝炎，而接受乙肝免疫球蛋白的25名配偶中有1人出现。乙肝免疫球蛋白组还出现了1例非乙型肝炎病例。5名接受对照球蛋白的人有亚临床乙肝感染的证据，而接受乙肝免疫球蛋白的人中只有1人有此证据。因此，乙肝免疫球蛋白似乎不仅能有效抑制疾病，还能抑制感染本身。现已证明，对于目前应被视为极高风险人群，乙肝免疫球蛋白具有预防价值。
